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Abstract
Background: HIV-1 replication is critically dependent upon controlled processing of its RNA and the activities
provided by its encoded regulatory factors Tat and Rev. A screen of small molecule modulators of RNA processing
identified several which inhibited virus gene expression, affecting both relative abundance of specific HIV-1 RNAs and
the levels of Tat and Rev proteins.
Results: The screen for small molecules modulators of HIV-1 gene expression at the post-transcriptional level
identified three (a pyrimidin-7-amine, biphenylcarboxamide, and benzohydrazide, designated 791, 833, and 892,
respectively) that not only reduce expression of HIV-1 Gag and Env and alter the accumulation of viral RNAs, but also
dramatically decrease Tat and Rev levels. Analyses of viral RNA levels by qRTPCR and RTPCR indicated that the loss
of either protein could not be attributed to changes in abundance of the mRNAs encoding these factors. However,
addition of the proteasome inhibitor MG132 did result in significant restoration of Tat expression, indicating that the
compounds are affecting Tat synthesis and/or degradation. Tests in the context of replicating HIV-1 in PBMCs confirmed that 791 significantly reduced virus replication. Parallel analyses of the effect of the compounds on host gene
expression revealed only minor changes in either mRNA abundance or alternative splicing. Subsequent tests suggest
that 791 may function by reducing levels of the Tat/Rev chaperone Nap1.
Conclusions: The three compounds examined (791, 833, 892), despite their lack of structural similarity, all suppressed
HIV-1 gene expression by preventing accumulation of two key HIV-1 regulatory factors, Tat and Rev. These findings
demonstrate that selective disruption of HIV-1 gene expression can be achieved.
Keywords: HIV-1, RNA processing, Tat, Rev, Small molecule inhibitors
Background
HIV-1 is heavily dependent upon the host cell RNA processing machinery for production of new virions. Following integration, transcription of the HIV-1 provirus
generates a single 9 kb transcript that is subsequently
processed through alternative splicing into over 40
mRNAs that fall into three classes; (1) unspliced (US),
9 kb mRNA encoding Gag and Gagpol, (2) singly spliced
(SS), 4 kb mRNAs used to synthesize Vif, Vpr, Vpu, and
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Env, and (3) multiply spliced (MS), 1.8 kb mRNAs used
to generate Tat, Rev, and Nef [1]. Extent of splicing of
the primary transcript is regulated by the efficiency of
the signals that form the splice sites themselves as well
as the presence of adjacent regulatory elements that act
to either promote (exon splicing enhancers, ESEs) or
suppress (intron splicing silencers, ISS, or exon splicing silencer, ESS) use of the adjacent splice site [1]. The
observation that mutation of a subset of these regulatory elements (ESSV, ESEtat) leads to dramatic perturbation in the viral mRNAs generated and substantially
reduces virus replication underlines the significance of
these splicing control mechanisms [2–4]. These findings
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also raise the possibility that manipulation of HIV-1 RNA
processing could be used as an antiviral strategy.
Multiple host factors contribute to the regulation of
HIV-1 RNA processing, many of which belong to the SR
and hnRNP family of splicing regulators [1]. Both overexpression and depletion studies have highlighted several
members of each family that play pivotal roles in regulating HIV-1 gene expression and virus replication [2,
5–11]. More relevant to the goal of the development of
therapeutics, several groups have identified small molecules (digoxin, chlorhexidine, IDC16, ABX464, 8-azaguanine, 5310150, 1C8) which appear to function at
different stages of HIV-1 RNA processing/expression to
block viral structural protein expression [12–17]. Both
digoxin and chlorhexidine were found to induce significant alterations in HIV-1 RNA abundance, with reductions in accumulation of both viral US and SS RNAs with
no change/increased accumulation of MS RNAs [12, 14].
Both compounds dramatically reduced Gag, Env, and Rev
expression with limited effects on Tat. In contrast, 8-azaguanine and 5350150 had similar effects as digoxin and
chlorhexidine on HIV-1 RNA accumulation and Gag/Env
synthesis but did not alter Tat or Rev levels [13]. Rather,
both compounds altered Rev subcellular distribution
putatively resulting in impaired Rev function. In contrast to the compounds listed above, IDC16 functions by
inhibiting generation of HIV-1 MS RNA without affecting US RNA levels, possibly by altering the function of
SRSF1 [15]. Consequently, there appear to be multiple
mechanisms/stages post-integration at which small molecules can act to impair expression of HIV-1 structural
proteins required for the assembly of new virions.
To expand the catalog of compounds affecting HIV-1
RNA processing/gene expression, we have tested a
library of RNA splicing modulators identified in a cell
based assay using alternative splicing of SMN2 as a
reporter (P. Stoilov, unpublished data). Of the compounds tested, we report here the characterization of
three,
3-(4-chlorophenyl)-5-methyl-N-(3-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
(designated
9147791 or 791), N-([2-(2-hydroxybenzoyl)hydrazino]
carbonothioyl}-4-biphenylcarboxamide
(designated
5227833 or 833), and 2-hydroxy-N′-(3-hydroxy-4methoxybenzylidene)benzohydrazide
(designated
5183892 or 892) as potent inhibitors of HIV-1 gene
expression. The compounds were found to suppress
HIV-1 gene expression in different cell based assays,
reducing accumulation of all viral proteins (Gag, Env, Tat
and Rev) tested. Furthermore, a subset of the compounds
blocked replication of HIV-1 in PBMCs and inhibited
growth of various HIV-1 strains including those resistant
to several current therapeutics. Changes in viral protein
expression were accompanied by changes in HIV-1 RNA

Page 2 of 21

accumulation, all compounds inducing a reduction in US
and SS RNA abundance but without significant alterations in MS RNA levels. The compounds had only limited effects on splice site usage that would not account for
the loss of Rev and Tat, suggesting that they were affecting Tat/Rev synthesis and/or degradation. Consistent
with this hypothesis, addition of the proteasome inhibitor MG132 was found to result in partial restoration of
Tat accumulation but not Gag. Parallel examination of
the effect of compounds on host RNA splicing revealed
that they had very limited effects, suggesting that the
response observed was not attributable to a radical alteration in spliceosome function/formation. Of the three,
791 was found to have the least effect on the host, with
further analyses determining that, of ~9000 genes surveyed by RNAseq, less than 1% had alterations in alternative exon inclusion of greater than 10%. Together, these
findings further establish that compounds can be used
to selectively inhibit HIV-1 gene expression at the posttranscriptional level. Further understanding of the mechanism by which these compounds act will help in the
refinement of this strategy to control HIV-1 replication.

Results
Identification of 791, 833, and 892 as suppressors of HIV‑1
protein expression

The success of digoxin as a potent inhibitor of HIV-1
gene expression, described previously by Wong et al.
[14], lead us to screen other small molecular compounds
for activity against HIV. Over sixty compounds identified
as RNA splicing modulators using the SMN2 mini-gene
reporter system (Dr. Peter Stoilov, University of West Virginia, unpublished) were tested for their ability to inhibit
HIV-1 gene expression. As shown in Fig. 1, treatment
of HeLa rtTA HIV∆Mls cells [12] containing a doxycycline-inducible HIV-1 provirus [18, 19] identified three
compounds, designated 791, 833, and 892, that reduced
HIV-1 viral production by 80–90% relative to DMSO
treatment (+Dox), in the low μM range. The three compounds differed in the number of five and six-numbered
rings they contained and lacked a steroid-ring structure
like digoxin and other cardiotonic steroids (Fig. 1a). Portions of the 791 structure resemble nucleotide bases,
while portions of 892 and 833 structures resemble
amido-groups. These compounds were structurally dissimilar to each other and to previously characterized
modulators of HIV-1 RNA processing digoxin, 8-azaguanine (8-aza), and 5350150 (150) [13, 14]. Parallel analysis determined that inhibition of HIV-1 replication with
compound treatment was dose-dependent. Analysis of
compound toxicity by both XTT and Trypan blue exclusion assays determined that for 791 and 833, cell viability was not affected at doses (20 and 10 µM, respectively)
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required to reduce Gag expression by >80%, although
some toxicity was observed at higher doses. Compound
833 showed some reduction in mitochondrial function as
indicated by XTT assays but no change in Trypan blue
exclusion up to 10 µM whereas a 90% reduction in Gag
expression was achieved at 1.5 µM (Fig. 1c–e; Table 1).
No difference in compound toxicity was observed in the
absence or presence of HIV-1 gene expression (Fig. 1c–e,
∓Dox). Both 791 and 833 maintained their inhibition of
HIV-1 gene expression in the context of CD4+ SupT1
cells (Additional file 1: Figure S1).

and B (HIV-1 IIIB) viruses as well as strains resistant to
reverse transcriptase, protease, or integrase inhibitors.
As shown in Fig. 3, both 833 and 791 yielded significant
reductions in HIV-1 replication of all viruses tested with
limited effects on cell viability (as assessed by forward
scatter/side scatter (FS/SS) and ViaCount, Fig. 3; Table 1
and Additional file 2: Figure S7). 892 displayed only modest inhibitory activity against all viruses at the doses
examined.

Compounds inhibit HIV‑1 replication in PBMCs and are
effective against drug resistant forms of HIV‑1

To understand the basis for the inhibition of virus production, we examined the effect of the compounds on
expression of multiple viral proteins. Following treatment
of HeLa rtTA HIV∆Mls cells and doxycycline induction
for 24 h, cell lysates were harvested and blots probed with
antibodies to the viral structural proteins Gag and Env,
as well as regulatory proteins Rev and Tat. Representative western blots from at least three independent experiments are shown (Fig. 4). All compounds reduced the
levels of p55, p41, and p24 Gag proteins and gp160 and
gp120 Env proteins relative to DMSO alone (Fig. 4a, b).
The effect of the compounds on viral regulatory proteins,
however, is very different from that observed with previously characterized HIV-1 inhibitors (Fig. 4c) [12–14].
All three compounds resulted in significant reduction in
accumulation of both Tat and Rev. Together, these results
suggest that 791, 833, and 892 inhibit HIV-1 protein
expression in vitro by blocking expression of both early
(Rev, Tat) and late (Gag, Env) HIV-1 proteins (Fig. 4).

The ability of the compounds to potently inhibit HIV-1
gene expression in the context of the cell lines tested
raised the question as to whether they would have similar effects on replicating virus in primary cells. Consequently, we tested the ability of 791, 833, or 892 to inhibit
HIV-1 BaL replication in peripheral blood mononuclear
cells (PBMCs) from healthy donors. PBMCs were activated for three days prior to infection with HIV-1 BaL
(multiplicity of infection, MOI < 0.01) and treatment
with DMSO, 791, 833, or 892. Cell culture medium from
compound-treated cells was sampled every 2 days to
measure the effect of compound treatment on virus production and cell viability. Inhibition of HIV-1 virus production in PBMCs by 791 was achieved in at least three
independent experiments using cells from 2–4 different
donors at doses (<5 µM) that did not affect cell viability
(representative data shown in Fig. 2). In contrast, 833
and 892 displayed toxicity at concentrations required to
block HIV-1 replication. Therefore, 791 inhibited HIV-1
replication in a mixed cell population even under in vitro
HIV infection conditions where cell infection rates are
substantially higher than in HIV+ patients. Furthermore,
791 maintains inhibitory activity in primary cells against
replication-competent HIV-1 at similar or lower concentrations than needed in HeLa cell lines, demonstrating
that the compound is active at low μM concentrations in
a relevant context.
As a further test of the compounds, we examined their
ability to inhibit replication of clade A (HIV-1 N54)

791, 833, and 892 block expression of HIV‑1 Gag, Env, Tat
and Rev

791, 833, and 892 reduce HIV‑1 US and SS RNA but not MS
RNA accumulation

To determine whether the dramatic loss of viral proteins is accompanied by changes in viral mRNA levels,
the effect of compound treatment on the abundance
of HIV-1 RNA classes was examined by qRT-PCR.
Total RNA was isolated from DMSO- or compoundtreated HeLa rtTA HIV∆Mls cells, and qRTPCR performed using forward and reverse primers specific to
β-actin (internal control for normalization) as well as
HIV-1 unspliced (US), singly-spliced (SS), and multiply

(See figure on next page.)
Fig. 1 Screen of RNA splicing modulators identifies three potent inhibitors of HIV-1 gene expression. a Structures of compounds tested. b HeLa
HIVrtTA∆Mls cells were incubated with 791 (30 µM), 833 (2 µM), or 892 (15 µM) for 24 h in the absence (−) or presence of (+) of Dox and media collected. Effect of compound treatment on HIV-1 virion accumulation in culture supernatant as measured by p24 antigen ELISA and expressed relative to DMSO-treated samples (N ≥ 16, ***p ≤ 0.001). Uninduced, DMSO-treated (DMSO, −Dox) samples were included as negative controls. At left,
dose response for 791 (c), 833 (d), or 892 (e) on HIV-1 virion production in culture supernatant was measured by p24 antigen ELISA and expressed
relative to p24 Gag levels in DMSO-treated samples (N ≥ 3, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001). At right, the effect of the compounds on cell
metabolism/viability, at the ranges of concentrations tested, was measured using an XTT assay or Trypan blue exclusion as a readout of viable cells
and expressed relative to DMSO-treated samples (N ≥ 3, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001). Error bars indicate standard error of the mean
(SEM)
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Table 1 Effect of compounds on HIV-1 gene expression and cell viability
HeLa

24STNLESG

CEM-GXR

PBMC

IC50 (μM)

CC50
XTT
(μM)

CC50
Trypan blue
(μM)

IC50

CC50
XTT

IC50

CC50
FSC/SSC
(μM)

CC50
ViaCount
(μM)

IC50
(μM)

CC50
Trypan blue
(μM)

791

8.2

>40

>40

26 μM

>60 μM

4.5 μM

>12

24

1.5

> 10

833

0.6

>10

3.5 μM

>20 μM

1.0 μM

>5

>5

1.6

3.0

892

1.8

≥40

>40

nd

nd

n/a

31

60

2.0

4.5

>40

The concentration of compounds that inhibit HIV gene expression by 50% (IC50) and the concentration that decreases cellular toxicity to 50% (CC50) relative to DMSOtreated cells are listed. Compound toxicity was measured by either a cellular metabolism assay (XTT). trypan blue exclusion, fluorescence-activated cell sorting (FACS)
or Guava ViaCount assay. For the CEM-GXR cells, the CC50 was based on the compound toxicity tn cells infected with a Clade B HIV-1 strain, while uninfected calls were
used for the ViaCount assay. FSC forward scatter, SSC side scatter, nd not done. n/a not available

spliced (MS) RNAs. Analysis of HIV-1 RNA abundance
revealed that the compounds reduced levels of HIV-1
US and SS RNAs with no significant changes in levels of MS RNA relative to DMSO alone. Uninduced,
DMSO-treated cells showed no viral RNA expression,
as expected (Fig. 5a). This data correlated with the
reduced levels of Gag, Env, and p14 Tat (Fig. 4) since
these proteins are encoded by HIV-1 US and SS RNAs.
However, the imbalance in viral RNA classes suggested
that the compounds may be altering viral RNA splicing,
a critical step in HIV-1 replication that relies heavily on
regulation of splicing involving many cellular factors
[1].
Given that HIV-1 MS RNA abundance is unaffected
by compound treatment but MS-encoded proteins, Rev
and Tat, are reduced, the compounds could be inducing changes in splice site usage to alter the levels of MS
RNA splice variants coding for these proteins. Hence,
we performed RT-PCR for MS RNAs to assess whether
the compounds altered usage of specific splice sites
within this class of RNAs. Although the HIV-1 proviral
genome in HeLa rtTA HIV∆Mls cells contains modifications, it recapitulates the splicing events of HIV-1 preRNA, so that the levels of most MS RNA isoforms (less
abundant isoforms are below the limit of detection) can
be analyzed using this method [20]. Amplified products
were visualized and the levels of HIV-1 MS RNA isoforms quantified by densiometric analysis and designated
according to size. (see Additional file 4: Figure S2 for a
description of the splice products indicated). No significant changes in splice site usage were observed upon 791
treatment relative to control (DMSO, +Dox) (Fig. 5b). In
contrast, 892 and 833 treatment caused a ~30% decrease
in levels of Rev1/2 and Nef RNAs and slightly increased
(<10%) Tat1 and Tat2 RNAs, relative to DMSO. Such
minor alterations in splice utilization coupled with the
lack of effect on MS RNA levels suggests that the loss
of HIV-1 regulatory proteins upon compound treatment cannot be attributed to a marked reduction of viral
MS RNAs encoding these proteins. Consequently, the

compounds are more likely to interfere with the translation of these MS RNAs or alter the stability of the proteins synthesized.
Compounds inhibit cytoplasmic accumulation of HIV‑1 US
RNA consistent with loss of Rev function

Since compound treatment resulted in loss of HIV-1
MS-encoded regulatory proteins Rev and Tat, but had
no appreciable effect on the abundance or splice site
usage within MS RNA, we hypothesized that the compounds may inhibit HIV-1 gene expression by perturbing Rev-mediated viral RNA transport, protein
synthesis, or protein stability. To assess the effect of the
compounds on the Rev-dependent export of incompletely spliced viral RNA, the subcellular localization
of HIV-1 US RNA and Gag was examined by fluorescent in situ hybridization (FISH). Since the compounds
induce loss of Rev protein (Fig. 4c), it was likely that
HIV-1 US RNA would not be exported to the cytoplasm
for subsequent virus particle assembly and translation
of viral structural proteins [21, 22]. To determine if
this was the case, HeLa rtTA HIV GagGFP (C7) cells,
which express a GagGFP fusion protein, were treated
with DMSO or compounds as described above and
localization of HIV-1 US RNA assessed by FISH. Studies confirmed that this cell line had similar response to
compound addition as that detailed above (see Additional file 5: Figure S3). Induction of HIV-1 gene expression (DMSO, +Dox) results in US RNA localization in
both the nucleus and cytoplasmic region with strong
GagGFP expression throughout the cell (Fig. 6). Colocalization of viral US RNA and GagGFP is indicated
by the merged signal (yellow). In contrast, treatment
with 833, 791, or 892 prevented cytoplasmic accumulation of HIV-1 US RNA and reduced GagGFP levels
relative to DMSO treatment (N ≥ 3). No US RNA and
GagGFP expression was detected in uninduced cells,
as expected. The effect of the compounds on HIV-1
US RNA and GagGFP expression is consistent with US
RNA abundance and Gag protein expression measured
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Fig. 2 791 inhibits HIV-1 replication in PBMCs with limited toxicity. a Average data of HIV-1 BaL virus replication in three different donors over a
period of 8 days post-infection (p.i.,) as measured by p24 antigen ELISA (N = 4, 3 donors). PBMCs were infected with HIV-1 BaL (MOI < 0.01) and
treated on days 0 and 4 post infection with DMSO, AZT (3.74 μM), 791, 833, or 892 at the concentrations indicated. Error bars indicate standard
error of the mean (SEM). The effect of increasing concentrations of 791 (b), 833 (c), or 892 (d) on HIV-1 BaL virion production in PBMCs. Following
infection, indicated doses of compound were added, media harvested after 6 days, virus replication measured by p24 antigen ELISA and expressed
relative to p24 Gag levels in DMSO-treated cultures (N ≥ 3, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001). The effect of the compounds on cell viability
was measured by trypan blue exclusion as a percentage of total cells and expressed relative to percent cell viability with DMSO-treatment

by qRT-PCR and SDS-PAGE, respectively. Furthermore,
the nuclear retention of US RNA upon compound treatment is consistent with the loss of Rev protein observed
by western blotting (Fig. 4). These results suggest that
the compounds prevent the early to late transition in
HIV-1 gene expression.

791 and 833 do not affect total protein synthesis

The loss of expression of all HIV-1 proteins tested raised
the possibility that some or all of the compounds were
acting as general inhibitors of protein synthesis. To
address this hypothesis, the effect of compound treatment on protein synthesis was measured by surface

(See figure on next page.)
Fig. 3 791 and 833 inhibit replication of multiple HIV-1 variants. To assess the ability of compounds to inhibit replication of different HIV-1 strains
and viral variants having resistance to HIV-1 inhibitors, CEM-GXR cells, containing an exogenous Tat-driven LTR-GFP expression cassette, were
infected with clade A (97USSN54 (N54)) or clade B (IIIB) strains of HIV-1 or pNL4-3 virus having mutations conferring resistance to protease inhibitors
(PRI, strain 2948), reverse transcriptase inhibitors (RTI, strain E00443)), or integrase inhibitors (INI, strain 11845). See Additional file 3: Table 1 for a
full description of the drug resistant viruses used. Cell cultures containing serial dilutions of the molecule in the final concentrations of a 0.725–
46.87 μM for 791, b 0.156–5 μM for 833, or c 1.95–62.5 μM for 892. Antiviral activity was evaluated measuring frequency of HIV-1 infected (GFP positive) cells by flow cytometric analysis. For viable cell counts, the gate in a flow cytometer was set to cover 95% of the freshly passaged uninfected
CEM-GXR cell or ViaCount™ was used
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addition of puromycin to the media 30 min prior to harvest and measurement of incorporation by western blot
using a monoclonal antibody to puromycin. Analysis of
blots in the presence and absence of HIV-1 gene expression (∓Dox) indicated that both 791 and 833 had little or
no effect while 892 resulted in a small reduction (~25%)
in protein synthesis relative to DMSO at doses that significantly reduced HIV-1 protein expression (Fig. 7).
In contrast, cells treated with cycloheximide (CHX), an
inhibitor of translation elongation, or without puromycin
(No puro), had little or no signal, respectively, confirming
that signals detected were newly synthesized puromycintagged polypeptides.
791, 833, and 892 alter Tat protein synthesis and/or
stability

Fig. 4 Compound treatment dramatically decreases the expression
of HIV-1 structural and regulatory proteins. HeLa HIVrtTA∆Mls cells
were incubated with DMSO (control), 791 (30 µM), 833 (2 µM), or 892
(15 µM) for 24 h in the absence (−) or presence of (+) of Dox. Cells
were subsequently harvested and shown are representative blots
showing the effect of the compounds on HIV-1 a Gag protein and b
Env protein expression relative to GAPDH or α-tubulin expression as
loading controls (SDS-PAGE, N ≥ 3). Images showing p55, p41, and
p24 expression were cropped from same blot visualized at different
exposure times due to difference in abundance of these isoforms. c
Representative blots showing the effect of the compounds on HIV-1
Rev and Tat protein expression relative to α-tubulin expression as
loading control (SDS-PAGE, N ≥ 3). For the blot shown, lanes were
cropped from the same blot to show compound-treated lanes adjacent to DMSO-treated control lanes

sensing of translation (SUnSET) [23]. This nonradioactive method uses puromycin, a structural analog of aminoacyl tRNAs produced by Streptomyces alboniger, to
monitor protein synthesis since it becomes incorporated
into nascent peptides when inducing chain termination.
Consequently, new protein synthesis was measured by

Given the absence of an effect on total protein synthesis
that could account for the loss of Tat or Rev expression, it
was of interest to examine whether the compounds had a
more direct effect on HIV-1 protein synthesis or stability. Initial attempts to evaluate whether the compounds
directly affected Tat protein decay did not detect any
measurable changes in the kinetics of Tat protein loss
(see Additional file 6: Figure S4). To determine whether
the change in Tat expression could be attributed to lack
of synthesis or enhanced turnover, we tested the effect
of MG132 (a proteasome inhibitor) treatment on Tat
and Gag protein levels in the presence and absence of
compound. As shown in Fig. 8a, b, addition of MG132
resulted in significant accumulation of both Tat isoforms
in the presence of 791, 833, or 892. In contrast, MG132
did not restore production of HIV-1 Gag to any significant level relative to that seen in the absence of MG132.
The ability to restore Tat protein accumulation with
MG132 confirms that Tat protein synthesis is occurring
in the presence of the compounds. To assess whether the
compounds were acting in a manner similar to another
recently described small molecule modulator of Tat
stability [24], we examined changes in cellular p53 levels upon compound addition. In contrast to curcumin,
which reduces both Tat and p53 levels [24], addition of
833 or 892 had no effect on p53 expression while 791
increased the levels of this host factor by approximately
twofold (Fig. 8c, d).
791, 833, and 892 did not significantly affect cellular RNA
alternative splicing

Given the dramatic shift in HIV-1 RNA accumulation,
it was of interest to determine to what extent alternative
splicing of the host cell RNAs was altered. As an initial
measure, we evaluated the effect of compound treatment
on alternative splicing of 73 select endogenous transcripts
(see Additional files 7, 8, 9: Tables S2, S3, S4) by RT-PCR

Balachandran et al. Retrovirology (2017) 14:7
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Fig. 5 The compounds decrease the levels of HIV-1 US and SS RNAs but do not dramatically alter splice site usage. HeLa HIVrtTA∆Mls cells were incubated with 791 (30 µM), 833 (2 µM), or 892 (15 µM) for 24 h in the absence (−) or presence of (+) of Dox, then cells collected and total RNA extracted. a
Top schematic of HIV-1 genome with the positions of the forward and reverse primers used for qRT-PCR analysis indicated by the arrows. US unspliced,
SS singly spliced and MS multiply spliced. Bottom, quantification of viral mRNA levels in compound-treated samples were normalized to β-actin and the
mean mRNA levels expressed relative to DMSO-treatment (N ≥ 7, **p ≤ 0.01, and ***p ≤ 0.001). Error bars indicate standard error of the mean (SEM). b
Top, schematic of HIV-1 genome with the positions of the forward and reverse primers used to amplify the 1.8 kb class of HIV-1 RNAs indicated by the
arrows. Left representative RT-PCR gel with HIV-1 MS isoforms labelled on the right according to Purcell and Martin, 1993 (N ≥ 3). Right quantification of
PCR products was performed by densiometry analysis with the level of each isoform expressed as the mean percentage of the total density of all RNA
species within the sample (N ≥ 7, **p ≤ 0.01, and ***p ≤ 0.001. Error bars indicate standard error of the mean (SEM)
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Fig. 6 791, 833, and 892 inhibit cytoplasmic accumulation of HIV-1 US RNA. HeLa rtTA HIV GagGFP C7 cells were treated with 791 (30 µM), 833
(2 µM), or 892 (15 µM) for 4 h prior to Dox induction. Cells were fixed 24 h after Dox addition and processed for FISH using probes to HIV-1 US RNA.
Representative fluorescent in situ hybridization images of cells treated with DMSO or the indicated compounds (N ≥ 3). Cells were viewed at 630X
(oil immersion) magnification. Images are cropped to show a representative field of view

using RNA isolated from DMSO and compound-treated
HeLa rtTA HIV∆Mls cells and quantitated by capillary
electrophoresis of the amplicons generated. The ‘percent
spliced in’ or PSI in annotated cassette exons was compared to DMSO treatment (Fig. 9, Additional files 7, 8,
9: Tables S2, S3, S4). Changes in alternative splicing of
endogenous genes/transcripts with |ΔPSI| ≥ 10 and 20%
are represented as red and yellow dots, respectively, and a
subset of these genes are labelled next to their respective
data points. Treatment with 791 showed no appreciable
changes in alternative splicing of the examined events as
most events fell along the theoretical diagonal dotted line
depicting no difference between compound and DMSO

treatments (Pearson correlation coefficient, R = 0.97).
Both 833 and 892 increased and decreased exon inclusion in a small subset of transcripts as indicated by the
points falling above or below the diagonal line, but overall showed a strong correlation with DMSO treatment
(R = 0.94). Of note, three alternatively spliced exons,
fgfr1op2, macf1, and gm130/golga2 were affected by all
three compounds.
To gain a more comprehensive evaluation of the effect
of 791 on host RNA alternative splicing and expression in
an unbiased fashion, paired-end RNAseq was performed
on RNA isolated from DMSO and 791 treated HeLa rtTA
HIV∆Mls cells (Fig. 10, Additional files 10, 11: Tables

Balachandran et al. Retrovirology (2017) 14:7

Fig. 7 791 and 833 have limited effect total protein synthesis. HeLa
HIVrtTA∆Mls cells were incubated with 791, 833, or 892 for 24 h at
doses indicated in the absence (−) or presence of (+) of Dox. Puromycin was added 30 min prior to harvest to measure total protein
synthesis using SUnSET. a Representative blot showing the effect of
the compounds on protein synthesis by puromycin labelling of nascent polypeptides (N ≥ 4). Samples not incubated with puromycin
(No Puro) or treated with cycloheximide (CHX) to block translation,
served as negative controls. b Quantification of protein synthesis
in the presence of the compounds was measured by the volume
intensity in each lane normalized to GAPDH intensity and expressed
relative to the DMSO-treatment (N ≥ 4, *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001). Error bars indicate standard error of the mean (SEM)

S5, S6). 791 was of particular interest given its consistent anti-HIV-1 activity in all assays (see Figs. 2, 3) and
more limited effect on cell growth upon extended culture
with cells (see Additional file 12: Figure S5). To calculate altered splicing events in response to 791 treatment,
the PSI in annotated cassette exons was determined and
compared to DMSO treatment. Based on the analysis of
biological duplicates of the ~10,000 alternatively spliced
events detected, 791 treatment resulted in very few
altered splicing events (2 AS events with exon inclusion/
exclusion ≥20% out of ~10,000 events) and correlated
well (R = 0.99) with values in DMSO treated samples
(Fig. 10a, b). The patterns of alternative splicing changes
observed by RNAseq were consistent with data from the
subset of AS events measured by the RT-PCR outlined
previously (Fig. 9). These results indicate that 791 did
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not significantly perturb cellular alternative splicing and
suggest that its inhibitory effect is selective to processes
involved in HIV-1 gene expression.
To determine whether 791 induced changes in gene
expression, alterations in mRNA abundance were examined and compared with changes in alternative RNA
splicing. The differential expression level of genes with
DMSO or 791 treatment was quantified as corrected
reads per kilobase of exon model per million mapped
(cRPKM) reads. The expression cutoff was a cRPKM
value of 0.5, corresponding to ≥10 reads that uniquely
mapped to a single genomic locus. Genes were described
as differentially expressed (DE) if the cRPKM fold change
was ≥2 or ≤0.5. Of 11,406 total genes examined, relatively few DE genes were detected following compound
treatment (Fig. 10c, Additional file 11: Table S6). In fact,
791 treatment changed only 0.46% of all genes analyzed
relative to DMSO treatment. Of the genes whose expression levels were altered, trib3, a putative protein kinase,
increased ninefold with 791 treatment relative to DMSO
addition (N = 2; see Additional file 11: Table S6). Comparison of changes in gene expression (GE) versus alternative splicing (AS) in response to 791 addition revealed
no overlap in the genes being affected (Fig. 10d).
Review of the RT-PCR data indicated that there were
alterations in the processing of RNA encoding Nap1, a
factor that interacts with both Tat and Rev and modulates their function [25, 26]. To assess whether our compounds were affecting Nap1 levels, western blots were
performed. As shown in Fig. 11, 892 had no effect on
Nap1 accumulation, while the effect of 833 was more variable. In contrast, 791 addition reduced expression of this
factor by approximately 50%.

Discussion
The central role that RNA processing plays in facilitating HIV-1 gene expression and replication makes it an
attractive target for therapeutic intervention [1, 15].
Recent studies by several groups have established that
small molecules (i.e. digoxin, chlorhexidine, 8-azaguanine, 5350150, IDC16, ABX464, 1C8) can be used to
effectively alter viral RNA processing with limited or no
effects on host cell viability [12–17]. Furthermore, the
demonstration that ABX464 can suppress HIV-1 replication in humanized mice and has beneficial effects even
after drug withdrawal indicates that such approaches
might have benefits over currently approved therapeutics
[16]. To expand the repertoire of small molecules affecting HIV-1 RNA processing, we have examined a subset
of modulators of SMN2 splicing for their capacity to alter
viral gene expression and identify three, 791, 833 and
892, as potent suppressors of HIV-1 protein expression
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Fig. 8 HIV-1 Tat expression can be rescued with proteasome inhibition by MG132. HeLa HIVrtTA∆Mls cells were incubated with 791 (30 µM), 833
(2 µM), or 892 (15 µM) for 24 h in the absence (−) or presence of (+) of Dox. Eight hours prior to harvest, MG132 was added as indicated to a subset
of the samples. a Representative blot showing effect of the compounds on HIV-1 Gag and Tat expression in the presence or absence of proteasome
inhibitor MG132, relative to DMSO treatment. GAPDH serves as loading control. b Summary of band intensities of HIV-1 p24 Gag and p14 and p16
Tat with each treatment relative to that of the DMSO control normalized to the corresponding GAPDH bands (N ≥ 3). Error bars depict standard
error of the mean and *, **, and *** indicate P values ≤ 0.05, 0.01, and 0.001, respectively. c, d To assess effect of compound addition on p53 expression, lysates were prepared from cells treated with 791 (30 µM), 833 (2 µM), or 892 (15 µM) and blots were probed for p53 and GAPDH. Shown are (c)
representative blot of results and d summary of quantitation of p53 expression after normalization using GAPDH

(Gag, Env, Tat, and Rev) in the context of the HeLa rtTA
HIV∆Mls cell line and 791 as an inhibitor of virus replication in PBMCs.
Given the activity of these compounds against HIV-1,
we investigated whether there was any existing description of these compounds in scientific literature or patent
applications that might provide insight into their mode
of action. To date, no studies on either 791 or 833 have
been published. However, there is limited information

available for 892 as well as structures similar to 791 in
other contexts. 892 and similarly structured compounds
have been identified as putative activators of AMP-activated protein kinase (AMPK) (WO 2012027548), modulators of telomerase binding (WO 20122097600 and US
201200160260), and activators of histone deacetylase 1
(HDAC1) (WO 2010011318). Interestingly, a compound
that is structurally similar to 892 was tested for inhibitory activity in the context of Hepatitis C virus (HCV)
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and shown to inhibit enzymatic activity of HCV protease
by ~57% at 50 μM [27]. Two compounds resembling 791
were tested for inhibition of cyclin dependent kinase
2 (CDK2)/cyclin A. These compound differ in the side

Fig. 9 791, 833, and 892 have limited effects on cellular alternative
splicing events. HeLa HIVrtTA∆Mls cells were incubated with a 791
(30 µM), b 833 (2 µM), or c 892 (15 µM) for 24 h in the presence of
Dox. Total RNA was harvested and used in RT-PCR assays to monitor
changes in 73 host genes known to undergo alternative splicing. Mean
alternative splicing changes (PSI, percent spliced in) were plotted
comparing DMSO and compound treatment (N = 3, RT-PCR). Diagonal
dotted line no difference between treatments. Dots above/below the
diagonal increased/decreased exon inclusion. |ΔPSI| ≥ 10 and 20% are
indicated as red and yellow dots (labelled), respectively. Statistically significant alternative splicing changes with |ΔPSI| ≤10% are indicated by
the gray dots (Student’s t test, two-tailed). Error bars not shown. Pearson
correlations (R values) are shown. See Additional files 7, 8, 9: Tables S2,
S3, S4 for a complete description of the data obtained

groups attached to the core pyrimidine ring structure.
One compound, designated 12a, has a phenol group in
place of the methyl group and a methyl group in place
of the phenol ring with a chlorine in 791. 12a was shown
to inhibit CDK2/cyclin A activity in vitro at an IC50 of
0.25 μM [28].
Despite the clear differences in structure between 791,
833 and 892, they have very similar effects on HIV-1
RNA processing and expression that are distinct from the
activities described for other inhibitors of this stage of
the virus lifecycle. Previously, we have demonstrated that
digoxin, 8-azaguanine and 5350150 block HIV-1 Gag and
Env expression and reduce accumulation of viral US and
SS RNAs but do not share the same alterations in Tat and
Rev [13, 14]. While digoxin reduced Rev accumulation,
expression of the Rev-independent form of Tat (p16) was
unaffected. In contrast, both 8-azaguanine and 5350150
had little effect on the levels of Tat or Rev protein but
altered the localization of Rev within the cell. While
studies on IDC16 and ABX464 have shown alterations
in HIV-1 RNA processing and reduced virus replication,
there is no report of their effects on expression of Tat or
Rev [15, 16]. However, the effects of 791, 833, and 892 on
viral RNA accumulation are comparable to the changes
seen upon inhibition of Rev-induced transport by leptomycin B [29, 30] (Additional file 13: Figure S6), where
treatment resulted in dramatic reduction of both US and
SS RNA levels with little or no change in MS RNA abundance. Therefore, the loss of Rev function, either due to
loss of the protein or Crm1 function, induces a shift in
HIV-1 RNA accumulation due to either enhanced turnover of the US and SS RNAs in the nucleus or their splicing to generate MS RNA. Consequently, the effect of 791,
833, and 892 may not be attributable to direct effects
on HIV-1 RNA processing but rather to changes in Rev
protein synthesis/stability. As predicted from the loss
of Rev, all three compounds induced nuclear retention
of the remaining viral US RNA within the cell (Fig. 6).
Consistent with action via reduction of Rev expression,
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Fig. 10 791 does not appreciably alter cellular gene expression or alternative splicing events. HeLa HIVrtTA∆Mls cells were incubated with 791
(30 µM) for 24 h. Cells were subsequently harvested for total RNA isolation and samples used for cDNA library preparation and Illumina sequencing. a Mean alternative splicing changes (PSI or percent spliced in) were plotted comparing DMSO and compound treatment (N = 2, RNA-seq).
|ΔPSI| ≥ 10% and 20% are represented as red and yellow dots, respectively. AS genes with exon inclusion/exclusion ≥20% are labelled. Statistically significant alternative splicing changes with |ΔPSI| ≤ 10% are indicated by the gray dots (Student’s t test, two-tailed). Error bars not shown.
b Summary of altered exon inclusion or exclusion (Incl. or Excl.) with compound treatment (RNAseq, N = 2). c Differentially expressed (DE) genes
described as cRPKM fold change ≥2 or ≤0.5 with compound treatment relative to DMSO treatment (p ≤ 0.05, 11,406 genes, N = 2). Fold change
distribution of differentially expressed genes based on compound treatment relative to DMSO treatment within the RNAseq dataset (p ≤ 0.05,
1020 genes, N = 2). d Venn diagrams comparing DE and AS (|ΔPSI| ≥ 10%) events with 791 (N = 2). See Additional files 10, 11: Tables S5 and S6 for a
complete description of the data obtained

compound addition induced only limited changes of the
~70 host RNA alternative splicing events initially tested
(Fig. 9). Subsequent, more detailed analysis of 791 further
validated these findings with only 15 of ~10,000 alternative splicing events showing changes of >10% in alternative exon inclusion (Fig. 10). 791 also had limited effects
on overall gene expression, inducing changes of <fivefold in 85 genes and <tenfold of 4 genes of the ~10,000
genes detected in the assay (Fig. 10). In contrast, previous studies have demonstrated that T cell activation
altered ~10% of >10,000 alternatively spliced events [31].
Although the compounds did not significantly affect
cellular splicing events in general, the splicing of three
exons, fgfr1op2, macf1, and gm130/golga2, was altered by

all three compounds. Given that only a few cellular alternatively spliced events were appreciably changed among
the total number of detected events, any changes that are
common among the compounds would be predicted to
be involved in their shared activity as inhibitors of HIV-1
gene expression.
The macf1, gm130/golga2, and fgfr1op2 genes encode
microtubule-actin crosslinking factor 1 (MACF1), Golgin A2, and fibroblast growth factor receptor 1 oncogene
partner 2 (FGFR1OP2), respectively. MACF1 is a large
protein that forms bridges between different cytoskeletal
elements and has been shown to regulate microtubule
dynamics by GSK3 signaling in skin stem cells and developing neurons [32, 33]. These studies found that GSK3
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Fig. 11 791 addition reduces levels of the protein chaperone Nap1.
HeLa HIVrtTA∆Mls cells were incubated with 791 (30 µM), 833 (2 µM),
or 892 (15 µM) for 24 h in the absence (−) or presence of (+) of
Dox. Cell lysates were harvested, fractionated on SDS-PAGE gels and
probed for Nap1. Blots were reprobed for GAPDH to confirm sample
loading. a Representative western blot and b summary of Nap1 levels
detected after normalization for protein loading

binds and phosphorylates MACF1, inhibiting MACF1’s
ability to bind microtubules [32, 33]. Thus, MACF1
appears to be a downstream target of GSK3 signaling
and further suggests that the compounds may impact
the GSK3/Wnt signaling pathway. Similarly, Golgin A2
appears to be involved in cytoskeletal signaling pathways
that regulate microtubule dynamics, as well as roles in
the maintenance of the Golgi apparatus and secretory
pathway [34]. Golgin A2 is phosphorylated by cyclin
dependent kinase 1 (Cdk1)-cyclin B and cyclin dependent kinase 5 (Cdk5) [35, 36]. In turn, Golgin A2 binds and
promotes the auto-phosphorylation of yeast Ste20-like
kinases YST1 (human homologue is Stk25) and MST4,
implicating the involvement of Golgin A2 in the MAPK
signaling pathway [37]. In contrast to MACF1 and Golgin
A2, the function of FGFR1OP2 is unknown, but is predicted to be translated into an evolutionarily conserved
protein containing coiled-coil domains and may also play
a role in related FGFR1 signaling pathways [38].
There was no overlap between the alternatively spliced
and differentially expressed genes for 791 (Fig. 10d), consistent with mounting evidence from genome-wide studies in support of the understanding that most genes often
undergo alternative splicing changes in protein isoforms
without accompanying changes in overall transcript levels [31]. Only a few genes (84 for 791) were upregulated
among the 11,406 genes examined. Of the genes that
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were differentially expressed, trib3, the gene encoding
Tribbles pseudokinase 3 (TRIB3) was upregulated by over
ninefold upon 791 treatment. TRIB3 is a putative protein
kinase that is induced by transcription factor NFκB, and
involved in numerous cellular processes [39]. Some of its
roles include, inhibiting the activation of Akt, regulating
activation of MAP kinases, and inhibiting APOBEC3A
editing of nuclear DNA [39–41]. Since TRIB3 plays a role
in regulating the PI3K/Akt signaling pathway and there
is a dramatic difference in its expression with 791 treatment, it would be interesting to examine the involvement
of TRIB3 during HIV-1 replication.
In the absence of significant changes in HIV-1 MS RNA
abundance or shift in splice site usage upon addition of
any of the compounds, the basis for the loss of Tat and
Rev was not immediately evident. The limited effect on
overall protein synthesis (as measured by SUnSET, see
Fig. 7) indicates that the compounds are not general
inhibitors of mRNA translation. The ability of the proteasome inhibitor MG132 to restore a significant amount of
Tat accumulation indicates that Tat synthesis is occurring in the presence of the compounds. Tests to assess
whether any of the compounds could directly affect Tat
protein stability did not reveal any measurable changes
(Additional file 6: Figure S4). However, these studies
were performed by adding compound after translation
was blocked by cycloheximide, so only existing Tat was
measured. The failure to detect a decrease in p53 levels
similar to those induced by curcumin, another modulator of Tat stability [24], suggested that these compounds
are acting via different mechanisms. Our findings suggest
that the compounds might be inducing a state within the
cell that renders both Tat and Rev unstable and might
require time for the transition to occur. Consistent with
this hypothesis, we observed a reduction in Nap1 expression, a molecular chaperone and modulator of both Tat
and Rev function [25, 26] upon addition of 791 (Fig. 11).
Nap1 prevents the aggregation of Rev [25] and its overexpression increased Tat levels [26]. By binding Tat or Rev,
Nap1 may reduce their availability for degradation by the
proteasome.
In contrast to its effect on Tat, addition of MG132 did
not restore but reduced Gag expression in the presence
or absence of compound. Previously, Schubert et al. [42]
demonstrated that MG132-induced proteasomal inhibition severely decreases the budding, maturation, and
infectivity of HIV-1 by reducing the level of free ubiquitin in HIV-1-infected cells and thereby prevented monoubiquitination of p6gag required for virus assembly and
release. Thus, decreased p24 Gag levels with MG132
treatment is consistent with the requirement of functional proteasome for proteolytic processing of HIV-1
Gag [42].
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Taken together, these results indicate that the compounds 791, 833, and 892 inhibit HIV-1 gene expression
by inducing the loss of key early viral regulatory proteins,
which, in turn, leads to a perturbation in the balance
of HIV-1 RNAs and subsequent loss of viral structural
proteins. While the detailed mechanism by which these
compounds act remains to be determined, the description of their effects offer insights into new strategies to
alter HIV-1 RNA processing. In addition to being structurally dissimilar to digoxin, 8-Azaguanine, and 5350150,
these three compounds are also structurally distinct from
NB-506, a splicing inhibitor that specifically blocks the
kinase activity of DNA topoisomerase I [43], and ABX464
[16]. The fact that small molecular compounds with distinct structures can effect gene expression by modulating
pre-mRNA splicing (NB-506, digoxin), mRNA transport
(ABX464, 8-azaguanine, 5350150), and protein stability (791, 833, and 892) validates using small molecules as
tools to probe components of RNA processing implicated
in disease or viral infections. Furthermore, the similarities between the effects of these compounds and ABX464
on both HIV and cellular splicing events, suggest that
more precise targeting of the affected processes could be
used to inhibit HIV replication in vivo. There are many
challenges in translating the effect of small molecules
in vitro to their application as novel drugs in humans.
The three compounds described here may not be directly
applicable in patients, as their systemic effects and therapeutic dose ranges remain unknown. However, the ability of 791 to reduce HIV-1 replication in human PBMCs
confirms activity in the natural context of HIV-1 infection. 791 inhibited HIV-1 BaL (R5-tropic) replication
in peripheral blood mononuclear cells over 6 days post
infection with >80% cell viability at concentrations up to
7.5 µM (Fig. 2). These results illustrate the promise of targeting HIV-1 RNA processing as a novel approach for the
treatment of HIV-1 infection.

Methods
Indicator cell lines and viruses

Effects of compound treatment on HIV-1 gene expression were initially assessed in the context of HeLa rtTA
HIV∆Mls cells stably transduced with an inducible TetOn HIV-1 system (as previously described [12, 18, 19]).
The provirus was modified by either deletion in the
reverse transcriptase and integrase region of the pol gene
by an MlsI restriction digest (HeLa rtTA HIV∆Mls cell
line) or GFP fusion to Gag, deleting the PR and RT-coding regions (HeLa rtTA HIVGagGFP cell line). Tat and
its TAR binding site are inactivated so that HIV-1 gene
expression is only induced in the presence of doxycycline
(dox). All cell lines were maintained in Iscove’s modified
Delbecco’s medium (IMDM; Wisent) supplemented with
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10% (vol/vol) fetal bovine serum (FBS, Wisent), 1% penicillin/streptomycin (P/S, Wisent) and 0.2% Amphotericin
B (Wisent). Indicator cell line CEM-GXR was obtained
from Dr. Mark Brockman (Simon Fraser University).
The RTI-resistant virus (E00443) was obtained from Dr.
Zabrina Brumme (Simon Fraser University). The HIV-1
clade A (97USSN54 (N54)), HIV-1 clade B (IIIB), integrase inhibitor resistant virus (11845), protease inhibitor resistant virus (2948) were obtained through the NIH
AIDS Research and Reference reagent program, Division
of AIDS, NIAID, NIH).
Compound treatment assay

The compounds used in the treatment assay were
obtained from ChemBridge. All compounds were solubilized to 10 mM or 1 mM stock concentrations in dimethyl
sulfoxide (DMSO) and stored at −20 °C for subsequent
experiments. Cells were incubated for 3–5 h in the presence of the compounds prior to induction with doxycycline (Dox) at a final concentration of 2 μg/mL. 24 h post
compound treatment, culture medium was harvested,
adjusted to 1% Triton X-100, and incubated at 37 °C for
1 h for p24 antigen ELISA. Cells were harvested in 2 mM
EDTA, 1xPBS. RNA was isolated using Aurum Total
RNA extraction kits (Bio-Rad), while total protein was
extracted with RIPA buffer (1% NP-40, 0.1% SDS, 0.5%
sodium deoxycholate, 150 mM NaCl, 50 mM Tris–HCl).
To examine the effect of compounds on viral replication, studies were carried out in peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from
healthy (HIV-uninfected) volunteer blood donors as
described by Dobson-Belaire et al. [44]. Informed consent was obtained from participants in accordance with
the guidelines for conduct of clinical research at the University of Toronto and St. Michael’s Hospital, Toronto,
Ontario, Canada. Stored PBMCs were thawed, washed
with RPMI 1640 complete medium and cultured in RPMI
1640 complete medium containing 2 μg/mL of PHA-L
(Sigma-Aldrich) and 20 U/mL of IL-2 (BD Pharmingen)
for 72 h. Subsequently, cells were counted and a portion of the cells was separated to another tube for uninfected control treatments. The remaining PBMCs were
resuspended in media containing HIV-1 BaL at a multiplicity of infection (MOI) of approximately 0.01 and
infected by spinoculation, following which cells were
washed twice with room temperature RPMI 1640 complete medium and resuspended to a concentration of
5 × 105 cells/mL in complete RPMI 1640 containing
20 U/mL of IL-2. Compounds were added to infected
PBMCs or uninfected control PBMCs. Azidothymidine
(AZT, Sigma-Aldrich) was used as control treatment at a
final concentration of 3.74 μM. On day 4 post infection,
culture medium was replenished with the compounds
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and IL-2 in fresh complete RPMI 1640. On days 2, 4, 6
and 8 post infection, culture supernatant was harvested,
virus lysed by adjusting to 1% TritonX-100 and stored at
−20 °C for p24 antigen ELISA. A fraction of the culture
was harvested to assess percent cell viability by trypan
blue exclusion using Glasstic slides (Kova). Relative percent cell viability in compound treated samples versus
DMSO-control treated samples was calculated as follows:
(total viable cells/total cells)compound/(total viable cells/
total cells)DMSO.
To assess the activity of compounds against HIV-1
strains having resistance to various ART drugs, assays were
performed in the context of CEM-GXR cells. These cells
express CD4, CXCR4, and coreceptor, CCR5 as well as an
exogenous Tat-driven LTR-GFP expression cassette. Cultures were infected with different HIV-1 strains of interest, differing on their subtypes (A and B), and resistance to
three major drug targets (reverse transcriptase, protease,
and integrase). The culture contains serial dilutions of the
molecule in the final concentrations from 0.156 to 5 μM
for 833; 725 nM to 46.87 μM for 791; 1.95 to 62.5 μM for
892. Antiviral activity was evaluated in the assay by measuring inhibition of HIV-1 spread in a coculture of CEMGXR cells containing 1% of HIV-1 infected (GFP positive)
cells using flow cytometric analysis (GuavaSoft 2.2 software, Guava HT8, Millipore). To estimate the viable cell
counts, the gate in a flow cytometer (Guava HT8) was
set to cover 95% of the freshly passaged uninfected CEMGXR cell or using ViaCount™. The same parameter was
employed to gate viable cells in the inhibition assay and the
number of gated cells was obtained by GuavaSoft 2.2 software. For assays using ViaCount™, sample acquisition and
data analysis were performed with the selection of EasyFit
analysis feature using the ViaCount™ software module.
Analysis of protein expression

ELISA for p24 Gag antigen was performed on cell supernatants using kits purchased from Frederick National Laboratory for Cancer Research (Leidos) or XpressBio extended
range kit and performed according to manufacturer’s instructions. Protein concentration in cell lysates was quantified by
Bradford assay and equal amounts of protein run on 7, 10,
12, or 14% SDS-PAGE, depending on the protein of interest. Following transfer to PVDF (BioRad or Perkin-Elmer),
blots were blocked in either 5% Milk-PBS-T (5% Milk, 0.05%
Tween-20, 1× PBS) or 3% BSA-PBS-T (3% BSA, 0.05%
Tween-20, 1× PBS) prior to incubating with primary antibody (all diluted in 3% BSA-PBS-T). Primary antibodies used
were: purified mouse anti-p24 supernatant from anti-HIV-1
Gag hybridoma 183, mouse anti-gp120 hybridoma 902 (NIH
AIDS Reagent Program), mouse monoclonal antibody to
HIV-1 Rev (Abcam), rabbit polyclonal antibody to HIV-1 Tat
(Abcam), mouse monoclonal antibody to p53 (Santa Cruz),
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rabbit purified IgG for Nap1 (provided by L. Frappier), rabbit
polyclonal antibody to GAPDH (Sigma-Aldrich), or mouse
monoclonal antibody to α-Tubulin (Sigma-Aldrich). Following incubation with appropriate secondary antibody, blots
were visualized by ECL, ECL Plus (Perkin-Elmer), or Clarity
Western ECL substrate (BioRad). Quantification of the relative intensity of the detected bands was done using ImageLab
software and normalized to corresponding bands of the loading control (GAPDH or α-Tubulin).
Compound toxicity assays

Effects of compound treatment on cellular metabolism was assessed by an XTT-based in vitro toxicology
assay kit (Sigma-Aldrich) or Trypan blue exclusion (Life
Technologies) as proxy for degree of cytotoxicity and
expressed relative to DMSO control treatment. For measurement of cell viability using XTT, culture media was
removed after 24, 72, and 96 h of compound treatment,
replaced with 20% XTT solution and incubated at 37 °C
in a 5% CO2 humidified incubator for 2–6 h, and relative
cell viability was measured in compound treated cells relative to DMSO-treated cells. Cell viability measurements
in CEM-GXR cells are described above.
RNA analysis

Samples were processed and assayed as previously
described using the BioRad Aurum Total RNA Lysis
Kit (BioRad) as per manufacturer’s instructions with
the addition of Turbo DNase (Ambion). Purified RNA
(0.5–2 μg) was reverse transcribed using M-MLV (Invitrogen) to generate complementary DNA (cDNA). HIV-1
and actin mRNA levels in DMSO- and compoundtreated samples were quantified by qPCR using the Mastercycler ep realplex (Eppendorf ) as described by Wong
et al. [12]. Gene quantification was evaluated using the
absolute quantification method, normalized to β-actin
expression, and expressed relative to DMSO-treatment.
The effect of compound treatment on splice site selection within the HIV-1 MS RNA class was analyzed by
radioactive RT-PCR as described previously [20]. Radioactive reaction products were resolved on 6% denaturing
polyacrylamide gels (8 M Urea, 1xTBE) and detection
using a Typhoon 9400 PhosphorImager (Amersham).
Gel densitometry was performed using ImageJ software
(NIH) to calculate mRNA levels of HIV-1 MS mRNA isoforms, measured as the density of an individual isoform
divided by the total density of all visible viral RNA species in a sample.
Changes in HIV-1 US RNA subcellular distribution in
response to compound treatment was analyzed by fluorescent in situ hybridization in HeLa HIVrtTA GagGFP
cells, as described by Wong et al. [14]. Following washing to remove unbound probe, nuclei were stained with
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DAPI and images were acquired using a Leica DMR
microscope at 630× magnification.
To assess the effect of compounds on expression/alternative splicing of cellular RNA, two approaches were
used. For both, total RNA was prepared from DMSO or
compound-treated cells. In the first assay, samples were
assayed by medium throughput RT-PCR to determine
the inclusion levels of alternatively spliced exons and
splice sites located in 73 selected events. 73 primer sets
containing a fluorescently (5-FAM) labeled primer for
each, were used in RT-PCR. PCR products generated
were denatured in formamide and quantified using ABI
Prism capillary sequencer (Life Technologies). The fragment analysis was performed on the PeakScanner software (Life Technologies) in batch mode and automated
using custom scripts written in Python. The inclusion
level of each exon was calculated as the amount of transcripts carrying the alternative exon relative to the total
amount of all transcripts detected in the PCR reaction
and results are summarized for compound-treatment in
comparison to DMSO treatment. In the second assay,
extracted RNA was processed using the Illumina TruSeq
RNA Sample Preparation Kit (Illumina) according to the
manufacturer’s instructions. The cDNA library generated was validated (passed quality control on a Bioanalyzer 1000 DNA chip (Agilent)), normalized and pooled
for cluster generation. cDNA libraries were sequenced on
the Illumina HiSeq 2500 (paired-end, 125 bp) with version 4 chemistry following manufacturer’s protocols. The
full human genome and transcriptomic sequences were
downloaded from the UCSC Genome Browser (genome.
ucsc.edu) database and Ensembl (www.ensembl.org),
respectively, as described by Irimia et al. [45]. Exon annotations and genomic coordinates for alternative splicing
(AS) analysis were derived from tables downloaded from
the UCSC Genome Browser database. To determine gene
expression (GE) or alternative splicing (AS) changes in
an unbiased way, the effective number of unique mappable positions in each transcript (i.e. the effective length)
was determined by aligning sequences with unique transcriptomic alignment to the human genome using Bowtie [46]. Reads with one unique genomic alignment were
then aligned against the canonical transcriptome and,
for each transcript, the number of reads with one unique
transcriptomic alignment were counted. The expression
level of genes was quantified as corrected ‘reads per kilobase of exon model per million mapped reads’ (cRPKM),
a widely used metric to estimate gene expression levels.
The expression cutoff was 0.5 cRPKM, corresponding to
the transcript of the gene being present if there were ≥10
reads that mapped uniquely to a single genomic locus.
Approximately 19,847 Ensembl annotated protein-coding
genes were compared to create a gene list of differentially
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expressed genes. Genes were considered differentially
expressed if fold changes in cRPKM was ≥2 in compound-treated versus DMSO-treated samples.
To obtain the percent spliced in (PSI) estimation, the
following procedure was followed. Every internal exon
in each annotated transcript was considered a potential “cassette” exon as described previously [45]. Briefly,
each “cassette” AS event was defined by three exons:
C1, A and C2, where A was the alternative exon, and
C1 and C2 were the 5′ and 3′ constitutive exons, respectively. For each event, spliced junctions were defined as
follows: C1A (connecting exons C1 and A), AC2 (connecting exons A and C2), and one alternative junction,
C1C2 (connecting exons C1 and C2). For each sample,
the corresponding mRNA-Seq data were aligned against
the human genome using Bowtie, allowing for a maximum of two mismatches. Reads that did not map to the
genome were then aligned to the full non-redundant set
of junction sequences and, for each junction, the number
of reads with one unique alignment mapping to it were
counted. For each junction, the corresponding read count
was normalized for its mapping ability by multiplying the
read count by the ratio between the maximum number
of mappable positions and its effective number of unique
mappable positions (as defined above). The percent
inclusion, or “percent spliced-in” (PSI) value, for each
internal exon was defined as: PSI = 100× average (#C1A,
#AC2)/(#C1C2 + average(#C1A, #AC2)), where #C1A,
#AC2 and #C1C2 were the normalized read counts for
the associated junctions. Exons were considered alternative in a sample if 5 ≤ PSI ≤ 95. In addition “high confidence” PSI levels were defined as those PSI values that
fulfilled the following specific coverage and balance criteria: max(min(#C1A, #AC2), #C1C2) ≥5 AND min(#C1A,
#AC2) + #C1C2 ≥10 and |log2(#C1A/#AC2)| ≤1 OR
max(#C1A, #AC2) <#C1C2. The goal of the first criterion was to ensure enough read coverage for sufficient
precision and resolution in the estimation of PSI levels.
The goal of the second criterion was to exclude AS events
where there was a high imbalance in read counts between
the two junctions formed by exon inclusion since these
imbalances can confound PSI estimates for cassette AS
events. For comparison of AS levels between pairs of
samples, Pearson correlation was applied to PSI levels.
Events were considered differentially spliced between
DMSO- and compound-treated samples if changes in PSI
levels were ≥10.
Monitoring protein synthesis by SUnSET

The effect of the compounds on nascent protein synthesis
was measured by surface sensing of translation (SUnSET)
as described by Schmidt et al. [23]. Cells were incubated
with puromycin, an aminoacyl tRNA analog, to allow
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puromycin incorporation into newly translated peptides and prevention of further ribosomal elongation by
chain termination. To assess the effect of the compounds
on protein translation, cells were prepared and treated
as described above, but were incubated with 10 μg/mL
of puromycin for a period of 30 min prior to harvesting
cell lysates for protein analysis. Protein concentration of
cell lysates was quantified by Bradford assay and equal
amounts of protein (30–35 μg) was run on either 10% or
4–15% (gradient) gels. Following transfer to PVDF (BioRad), blots were probed with mouse monoclonal antibody to puromycin (anti-12D10, EMD Millipore). Blots
were developed using ECL Plus (Perkin-Elmer) or Clarity (BioRad) and imaged using the ChemiDoc MP Imager
(BioRad). To quantify the levels of protein synthesis, the
volume intensity in each lane of compound-treated sample was calculated relative to the DMSO-treated sample and normalized to GAPDH loading control using
ImageLab software (BioRad) from at least four independent experiments.
Effect of compounds on HIV‑1 Tat stability

To assess effect of compounds on HIV-1 Tat stability,
the decay of HIV-1 Tat levels was compared between
DMSO-treated and compound-treated protein lysates in
the presence of cycloheximide. In the first set of experiments, HIV-1 gene expression was induced with doxycylin (dox) for 24 h then 10 μg/mL cycloheximide was
added to block new protein synthesis in combination
with either DMSO or the compounds. Cells were harvested every 2 h and Tat protein levels measured by western blot. Quantification of the relative intensity of the
detected bands was performed using ImageLab software
(BioRad) and normalized to corresponding bands of the
loading control (GAPDH) from at least three independent experiments. To determine whether the compounds’
effect on HIV-1 gene expression could be reversed by
inhibition of the proteasome, compound treatment assay
was performed as previously described with the addition
of 10 μM MG132 (Sigma-Aldrich) to compound-treated
cells 8 h prior to harvesting. Equal amounts of protein
were run on 13 or 14% gels by SDS-PAGE, blotted and
probed with antibodies for Tat and GAPDH. Quantification of the relative intensity of the detected bands was
performed using ImageLab software (BioRad) and normalized to corresponding bands of the loading control
(GAPDH) from at least three independent experiments.
Statistical analysis

In vitro experiments were all performed on at least three
separate occasions and are represented as the mean ± the
standard error (SEM) of the experiment, unless otherwise stated. Statistical significance comparisons between
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two samples were calculated using the paired two-tailed
student’s t test (Microsoft Excel) and graphs were generated using Prism 5.0 software (GraphPad). Significant
differences are represented by comparison to DMSOtreated control samples with the following legend:
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Significance levels
of p ≤ 0.05 were considered statistically significant.

Additional files
Additional file 1: Figure S1. 791 and 833 Suppress HIV-1 Gene Expression in SupT1 24NESLG Cell Line. a Schematic of HIV-1 provirus used to
generated the stably transduced SupT1 cell line [47]. b Effect of 791 and
833 on Gag expression in SupT1 NLESG cells. Cells were treated with
indicated concentrations of 791/833 then HIV-1 expression induced by
PMA addition. Media harvested after 24 h was subsequently assayed using
Gag (p24) ELISA. Cell viability was measured by an XTT assay. 892 was not
active in this cell line at the concentrations tested
Additional file 2: Figure S7. Effect of compounds on CEM-GXR cell
viability. Evaluation of 791, 833, and 892 on CEM-GXR cell viability in the
Guava ViaCount assay. Cells were analyzed after 24 h incubation with the
compounds at the indicated concentrations ranging between 0–47 μM
(791), 0–5 μM (833), or 0–62.5 μM (892). Results are expressed as the
percentage (%) of viable cells relative to DMSO treatment ±SEM of two
independent experiments performed in triplicate. Cytotoxic concentration resulting in the death of 50% of the host cells (CC50) relative to
DMSO measured by ViaCount assay (Millipore) are listed in Table 1
Additional file 3: Table S1. Mutations in HIV-1 proteins associated with
resistance to ARVs
Additional file 4: Figure S2.Pattern of HIV-1 RNA splicing. Shown at
the top is the organization of the HIV-1 proviral genome indicating the
position of the multiple 5′ splice donor sites (SD1–SD4) and 3′ splice
acceptor sites (SA1–SA7) used in splicing of pre-mRNA. In the middle is
an illustration of the alternatively spliced RNAs generated by processing
of the HIV-1 genomic RNA. Indicated are the common (open boxes) and
alternative exons (closed boxes) used in the generation of the SS (4 kb)
and MS (1.8 kb) viral RNAs. At the bottom is a list of the nomenclature
used to refer to the exon composition of the individual RNAs generated
for both the SS and MS classes of HIV-1 RNAs
Additional file 5: Figure S3. Characterization of HeLa rtTA HIVGagGFP cell line. a Representative images of HeLa rtTA HIVGagGFP C7 cells
treated with DMSO in the absence (uninduced) or presence (induced) of
doxycyclin (N ≥ 3). Cells were viewed at 630X (oil immersion) magnification. Images are cropped to show a representative field of view. b The
dose range of the compounds which inhibit HIV-1 GagGFP expression
in HeLa rtTA HIVGagGFP C7 cells was measured by mean fluorescence
intensity and expressed relative to fluorescence intensity in DMSO-treated
samples (N ≥ 3, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001). The effect of the
compounds on cellular metabolism at the indicated concentrations was
measured using an XTT assay as a readout of viable cells and expressed
relative to absorbance reads of DMSO-treated samples (N ≥ 3, *p ≤ 0.05,
**p ≤ 0.01, and ***p ≤ 0.001). Error bars indicate standard error of the
mean (SEM)
Additional file 6: Figure S4. 791, 833 or 892 do not alter the half-life
of HIV-1 Tat relative to DMSO. a Representative blots showing the decay
of Tat protein in the presence of cycloheximide (10 µg/ml) and DMSO or
indicated compounds (N ≥ 3, except for 833, N = 1–2). MG132 (10 μM)
was added for 8 h as an additional control to determine whether inhibition of the proteasome prevents protein degradation. All uninduced
(unind.) and 0 h samples were treated with DMSO. GAPDH serves as loading control. b Summary of effect of compounds on HIV-1 Tat degradation.
Band volume intensities of both p14 and p16 Tat isoforms were calculated
for each treatment relative to that of the DMSO control treatment and
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were then normalized to corresponding GAPDH bands (N ≥ 3, except for
833, N = 1–2). Error bars depict standard error of the mean, if possible
Additional file 7: Table S2. Dataset from RT-PCR determination of the
alternative splicing changes in cells treated with 9147791
Additional file 8: Table S3. Dataset from RT-PCR determination of the
alternative splicing changes in cells treated with 5227833
Additional file 9: Table S4. Dataset from RT-PCR determination of the
alternative splicing changes in cells treated with 5193892
Additional file 10: Table S5. Dataset from RNA-seq showing genes with
alternative splicing changes in cells treated with 9147791
Additional file 11: Table S6. Dataset from RNA-seq quantitating the
expression levels of genes in cells treated with 9147791
Additional file 12: Figure S5. 791 has reduced toxicity in comparison to
833 and 892. The graph shows cell proliferation as measured by XTT assay
1, 3, and 4 days post-treatment with the compounds relative to DMSOtreated HeLa rtTA HIV∆Mls cells (N = 3). Error bars depict standard error
of the mean and *, **, and *** indicate P values ≤ 0.05, 0.01, and 0.001,
respectively
Additional file 13: Figure S6. Leptomycin B treatment reduces HIV-1 US
and SS RNA Accumulation. 293T cells were transfected with pHxbc2 R-/RI-,
an HIV-1 proviral clone which does not express either reverse transcriptase
or integrase. Following overnight incubation with transfection cocktail,
cells were washed and incubated in media ±20 nM leptomycin B (+LB)
for 24 h. Cells were subsequently harvested and total RNA extracted. Levels of HIV-1 US, SS and MS RNAs was determined by qRTPCR as outlined.
Shown is the result of N = 3 independent assays
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